Impact of calcitriol and PGD
Demyelination
Intranasal
Nanoparticles
Neuro-inflammation
Nose-to-brain
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
accepted:
26
01
2024
medline:
17
2
2024
pubmed:
17
2
2024
entrez:
17
2
2024
Statut:
aheadofprint
Résumé
Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system (CNS) in need of a curative treatment. MS research has recently focused on the development of pro-remyelinating treatments and neuroprotective therapies. Here, we aimed at favoring remyelination and reducing neuro-inflammation in a cuprizone mouse model of brain demyelination using nanomedicines. We have selected lipid nanocapsules (LNC) coated with the cell-penetrating peptide transactivator of translation (TAT), loaded with either a pro-remyelinating compound, calcitriol (Cal-LNC TAT), or an anti-inflammatory bioactive lipid, prostaglandin D
Identifiants
pubmed: 38366115
doi: 10.1007/s13346-024-01535-8
pii: 10.1007/s13346-024-01535-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture
ID : FNRS 1.E085.19
Organisme : Université Catholique de Louvain
ID : COVID mandate
Organisme : Université Catholique de Louvain
ID : Patrimoine
Organisme : Communauté française de Belgique
ID : ARC
Informations de copyright
© 2024. Controlled Release Society.
Références
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58. https://doi.org/10.1038/nri3871 .
doi: 10.1038/nri3871
pubmed: 26250739
Thompson AJ, et al. Multiple sclerosis. The Lancet. 2018;391(10130):1622–36. https://doi.org/10.1016/s0140-6736(18)30481-1 .
doi: 10.1016/s0140-6736(18)30481-1
Walton C, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841 .
doi: 10.1177/1352458520970841
pubmed: 33174475
pmcid: 7720355
Fatima M, et al. Therapeutic role of vitamin D in multiple sclerosis: an essentially contested concept. Cureus. 2022;14(6):e26186. https://doi.org/10.7759/cureus.26186 .
doi: 10.7759/cureus.26186
pubmed: 35911285
pmcid: 9311493
Burton JM, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–9. https://doi.org/10.1212/WNL.0b013e3181e1cec2 .
doi: 10.1212/WNL.0b013e3181e1cec2
pubmed: 20427749
pmcid: 2882221
Galoppin M, et al. Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications. Brain Commun. 2022;4(4):fcac171. https://doi.org/10.1093/braincomms/fcac171 .
doi: 10.1093/braincomms/fcac171
pubmed: 35813882
pmcid: 9260308
Baas D, et al. Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia. 2000;31(1):59–68. https://doi.org/10.1002/(sici)1098-1136(200007)31:1%3c59::aid-glia60%3e3.0.co;2-y .
doi: 10.1002/(sici)1098-1136(200007)31:1<59::aid-glia60>3.0.co;2-y
pubmed: 10816607
de la Fuente AG, et al. Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. J Cell Biol. 2015;211(5):975–85. https://doi.org/10.1083/jcb.201505119 .
doi: 10.1083/jcb.201505119
pubmed: 26644513
pmcid: 4674280
Shirazi HA, et al. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240–5. https://doi.org/10.1016/j.yexmp.2015.02.004 .
doi: 10.1016/j.yexmp.2015.02.004
pubmed: 25681066
pmcid: 4400846
Mengozzi M, et al. Vitamins D3 and D2 have marked but different global effects on gene expression in a rat oligodendrocyte precursor cell line. Mol Med. 2020;26(1):32. https://doi.org/10.1186/s10020-020-00153-7 .
doi: 10.1186/s10020-020-00153-7
pubmed: 32272884
pmcid: 7146914
Miao D, Goltzman D. probing the scope and mechanisms of calcitriol actions using genetically modified mouse models. JBMR Plus. 2021;5(1):e10434. https://doi.org/10.1002/jbm4.10434 .
doi: 10.1002/jbm4.10434
pubmed: 33553990
Janousek J, et al. Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Crit Rev Clin Lab Sci. 2022;1–38. https://doi.org/10.1080/10408363.2022.2070595 .
Smolders J, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol. 2013;72(2):91–105. https://doi.org/10.1097/NEN.0b013e31827f4fcc .
doi: 10.1097/NEN.0b013e31827f4fcc
pubmed: 23334593
Nystad AE, et al. Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS. 2014;122(12):1178–86. https://doi.org/10.1111/apm.12281 .
doi: 10.1111/apm.12281
pubmed: 24862867
Chiuso-Minicucci F, et al. Treatment with vitamin D/mog association suppresses experimental autoimmune encephalomyelitis. PLoS ONE. 2015;10(5):e0125836. https://doi.org/10.1371/journal.pone.0125836 .
doi: 10.1371/journal.pone.0125836
pubmed: 25965341
pmcid: 4428830
Haghmorad D, et al. Prevention and treatment of experimental autoimmune encephalomyelitis induced mice with 1, 25-dihydroxyvitamin D3. Neurol Res. 2019;41(10):943–57. https://doi.org/10.1080/01616412.2019.1650218 .
doi: 10.1080/01616412.2019.1650218
pubmed: 31402771
Parastouei K, et al. The effect of calcitriol and all-trans retinoic acid on T-bet, IFN-gamma, GATA3 and IL-4 genes expression in experimental autoimmune encephalomyelitis. APMIS. 2020;128(11):583–92. https://doi.org/10.1111/apm.13073 .
doi: 10.1111/apm.13073
pubmed: 32865844
de Oliveira LRC, et al. Calcitriol prevents neuroinflammation and reduces blood-brain barrier disruption and local macrophage/microglia activation. Front Pharmacol. 2020;11:161. https://doi.org/10.3389/fphar.2020.00161 .
doi: 10.3389/fphar.2020.00161
pubmed: 32226379
pmcid: 7080989
Crocker JF, et al. The comparative toxicity of vitamin D metabolites in the weanling mouse. Toxicol Appl Pharmacol. 1985;80(1):119–26. https://doi.org/10.1016/0041-008x(85)90106-1 .
doi: 10.1016/0041-008x(85)90106-1
pubmed: 3875164
Wingerchuk DM, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(9):1294–6. https://doi.org/10.1136/jnnp.2004.056499 .
doi: 10.1136/jnnp.2004.056499
pubmed: 16107372
pmcid: 1739797
Azari AA, et al. Hydration with saline decreases toxicity of mice injected with calcitriol in preclinical studies. J Environ Pathol Toxicol Oncol. 2013;32(3):241–4. https://doi.org/10.1615/jenvironpatholtoxicoloncol.2013007532 .
doi: 10.1615/jenvironpatholtoxicoloncol.2013007532
pubmed: 24266410
pmcid: 4016973
Lung BE, Mowery ML, Komatsu DEE. Calcitriol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 30252281.
Heurtault B, Saulnier P, Pech B, Proust JE, Richard J, Benoit JP. Lipidic nanocapsules: preparation process and use as drug delivery systems. Patent No. WO02688000. 2000.
Mwema A, et al. Lipid nanocapsules for the nose-to-brain delivery of the anti-inflammatory bioactive lipid PGD(2)-G. Nanomedicine. 2022;1:102633. https://doi.org/10.1016/j.nano.2022.102633 .
doi: 10.1016/j.nano.2022.102633
Huynh NT, et al. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379(2):201–9. https://doi.org/10.1016/j.ijpharm.2009.04.026 .
doi: 10.1016/j.ijpharm.2009.04.026
pubmed: 19409468
Carradori D, et al. NFL-lipid nanocapsules for brain neural stem cell targeting in vitro and in vivo. J Control Release. 2016;238:253–62. https://doi.org/10.1016/j.jconrel.2016.08.006 .
doi: 10.1016/j.jconrel.2016.08.006
pubmed: 27503706
Carradori D, et al. Retinoic acid-loaded NFL-lipid nanocapsules promote oligodendrogenesis in focal white matter lesion. Biomaterials. 2020;230:119653. https://doi.org/10.1016/j.biomaterials.2019.119653 .
doi: 10.1016/j.biomaterials.2019.119653
pubmed: 31837824
Labrak Y, et al. Impact of anti-PDGFRalpha antibody surface functionalization on LNC uptake by oligodendrocyte progenitor cells. Int J Pharm. 2022;618:121623. https://doi.org/10.1016/j.ijpharm.2022.121623 .
doi: 10.1016/j.ijpharm.2022.121623
pubmed: 35231547
Alhouayek M, et al. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc Natl Acad Sci U S A. 2013;110(43):17558–63. https://doi.org/10.1073/pnas.1314017110 .
doi: 10.1073/pnas.1314017110
pubmed: 24101490
pmcid: 3808642
Alhouayek M, et al. The endogenous bioactive lipid prostaglandin D2-glycerol ester reduces murine colitis via DP1 and PPARgamma receptors. FASEB J. 2018;32(9):5000–11. https://doi.org/10.1096/fj.201701205R .
doi: 10.1096/fj.201701205R
pubmed: 29630407
Buisseret B, et al. Prostaglandin D2-glycerol ester decreases carrageenan-induced inflammation and hyperalgesia in mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(5):609–18. https://doi.org/10.1016/j.bbalip.2019.01.009 .
doi: 10.1016/j.bbalip.2019.01.009
pubmed: 30684679
Zirngibl M, et al. Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener. 2022;17(1):34. https://doi.org/10.1186/s13024-022-00538-8 .
doi: 10.1186/s13024-022-00538-8
pubmed: 35526004
pmcid: 9077942
Burrows DJ, et al. Animal models of multiple sclerosis: From rodents to zebrafish. Mult Scler. 2019;25(3):306–24. https://doi.org/10.1177/1352458518805246 .
doi: 10.1177/1352458518805246
pubmed: 30319015
Kipp M, et al. Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Scler Relat Disord. 2012;1(1):15–28. https://doi.org/10.1016/j.msard.2011.09.002 .
doi: 10.1016/j.msard.2011.09.002
pubmed: 25876447
Avsar T, et al. Investigation of neuro-inflammatory parameters in a cuprizone induced mouse model of multiple sclerosis. Turk J Biol. 2021;45(5):644–55. https://doi.org/10.3906/biy-2104-88 .
doi: 10.3906/biy-2104-88
pubmed: 34803461
pmcid: 8574193
Leo H, Kipp M. Remyelination in multiple sclerosis: findings in the cuprizone model. Int J Mol Sci. 2022;23(24). https://doi.org/10.3390/ijms232416093 .
Lloyd AF, et al. Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat Neurosci. 2019;22(7):1046–52. https://doi.org/10.1038/s41593-019-0418-z .
doi: 10.1038/s41593-019-0418-z
pubmed: 31182869
pmcid: 6597360
Lourenco T, et al. Modulation of oligodendrocyte differentiation and maturation by combined biochemical and mechanical cues. Sci Rep. 2016;6:21563. https://doi.org/10.1038/srep21563 .
doi: 10.1038/srep21563
pubmed: 26879561
pmcid: 4754901
Miron VE, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16(9):1211–8. https://doi.org/10.1038/nn.3469 .
doi: 10.1038/nn.3469
pubmed: 23872599
pmcid: 3977045
Morell P, et al. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci. 1998;12(4–5):220–7. https://doi.org/10.1006/mcne.1998.0715 .
doi: 10.1006/mcne.1998.0715
pubmed: 9828087
Mu HF, et al. Distinctive functional deficiencies in axonal conduction associated with two forms of cerebral white matter injury. CNS Neurosci Ther. 2019;25(9):1018–29. https://doi.org/10.1111/cns.13155 .
doi: 10.1111/cns.13155
pubmed: 31140740
pmcid: 6698976
De Berdt P, et al. Stem cells from human apical papilla decrease neuro-inflammation and stimulate oligodendrocyte progenitor differentiation via activin-A secretion. Cell Mol Life Sci. 2018;75(15):2843–56. https://doi.org/10.1007/s00018-018-2764-5 .
doi: 10.1007/s00018-018-2764-5
pubmed: 29417177
Natarajan C, Yao SY, Sriram S. TLR3 agonist poly-IC induces IL-33 and promotes myelin repair. PLoS ONE. 2016;11(3):e0152163. https://doi.org/10.1371/journal.pone.0152163 .
doi: 10.1371/journal.pone.0152163
pubmed: 27022724
pmcid: 4811556
Sung HY, et al. Down-regulation of interleukin-33 expression in oligodendrocyte precursor cells impairs oligodendrocyte lineage progression. J Neurochem. 2019;150(6):691–708. https://doi.org/10.1111/jnc.14788 .
doi: 10.1111/jnc.14788
pubmed: 31165473
Parastouei K, et al. The effect of 1, 25(OH)2 D3 (calcitriol) alone and in combination with all-trans retinoic acid on ROR-gammat, IL-17, TGF-beta, and FOXP3 gene expression in experimental autoimmune encephalomyelitis. Nutr Neurosci. 2018;21(3):210–8. https://doi.org/10.1080/1028415X.2016.1263039 .
doi: 10.1080/1028415X.2016.1263039
pubmed: 27996890
Oveland E, et al. 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochem Int. 2018;112:267–77. https://doi.org/10.1016/j.neuint.2017.08.008 .
doi: 10.1016/j.neuint.2017.08.008
pubmed: 28818673
Zendedel A, Beyer C, Kipp M. Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci. 2013;51(2):567–72. https://doi.org/10.1007/s12031-013-0026-4 .
doi: 10.1007/s12031-013-0026-4
pubmed: 23666824
Gartziandia O, et al. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces. 2015;134:304–13. https://doi.org/10.1016/j.colsurfb.2015.06.054 .
doi: 10.1016/j.colsurfb.2015.06.054
pubmed: 26209963
Goncalves J, et al. Nose-to-brain delivery of levetiracetam after intranasal administration to mice. Int J Pharm. 2019;564:329–39. https://doi.org/10.1016/j.ijpharm.2019.04.047 .
doi: 10.1016/j.ijpharm.2019.04.047
pubmed: 31015006
Goncalves J, et al. Pre-clinical assessment of the nose-to-brain delivery of zonisamide after intranasal administration. Pharm Res. 2020;37(4):74. https://doi.org/10.1007/s11095-020-02786-z .
doi: 10.1007/s11095-020-02786-z
pubmed: 32215749
Nystad AE, Torkildsen O, Wergeland S. Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. J Neuroimmunol. 2018;321:61–5. https://doi.org/10.1016/j.jneuroim.2018.05.016 .
doi: 10.1016/j.jneuroim.2018.05.016
pubmed: 29957389
Jia Y, et al. Cordycepin (3’-deoxyadenosine) promotes remyelination via suppression of neuroinflammation in a cuprizone-induced mouse model of demyelination. Int Immunopharmacol. 2019;75:105777. https://doi.org/10.1016/j.intimp.2019.105777 .
doi: 10.1016/j.intimp.2019.105777
pubmed: 31357085
Zhang Y, et al. A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination. Proc Natl Acad Sci USA. 2020;117(16):9082–93. https://doi.org/10.1073/pnas.2000208117 .
doi: 10.1073/pnas.2000208117
pubmed: 32253301
pmcid: 7183235
Honarvar F, et al. Ursolic acid enhances myelin repair in adult mice brains and stimulates exhausted oligodendrocyte progenitors to remyelinate. J Mol Neurosci. 2022;72(10):2081–93. https://doi.org/10.1007/s12031-022-02059-x .
doi: 10.1007/s12031-022-02059-x
pubmed: 35976486
Liu L, et al. Ginsenoside Rg1 promotes remyelination and functional recovery in demyelinating disease by enhancing oligodendrocyte precursor cells-mediated myelin repair. Phytomedicine. 2022;106:154309. https://doi.org/10.1016/j.phymed.2022.154309 .
doi: 10.1016/j.phymed.2022.154309
pubmed: 35994846
Zhu Y, et al. Stemazole promotes oligodendrocyte precursor cell survival in vitro and remyelination in vivo. Int J Mol Sci. 2022;23(18):10756. https://doi.org/10.3390/ijms231810756 .
doi: 10.3390/ijms231810756
pubmed: 36142668
pmcid: 9500784
Bourganis V, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337–62. https://doi.org/10.1016/j.ejpb.2018.05.009 .
doi: 10.1016/j.ejpb.2018.05.009
pubmed: 29733950
Chatterjee B, et al. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019;565:258–68. https://doi.org/10.1016/j.ijpharm.2019.05.032 .
doi: 10.1016/j.ijpharm.2019.05.032
pubmed: 31095983
Melchor GS, et al. Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression. ACS Pharmacol Transl Sci. 2019;2(6):372–86. https://doi.org/10.1021/acsptsci.9b00068 .
doi: 10.1021/acsptsci.9b00068
pubmed: 32259071
pmcid: 7088971
Villoslada P, Steinman L. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opin Investig Drugs. 2020;29(5):443–59. https://doi.org/10.1080/13543784.2020.1757647 .
doi: 10.1080/13543784.2020.1757647
pubmed: 32299268
Allanach JR, et al. Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: a systematic review. Mult Scler. 2022;28(1):29–48. https://doi.org/10.1177/13524585211008760 .
doi: 10.1177/13524585211008760
pubmed: 33870797
Starost L, et al. Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis. Acta Neuropathol. 2020;140(5):715–36. https://doi.org/10.1007/s00401-020-02217-8 .
doi: 10.1007/s00401-020-02217-8
pubmed: 32894330
pmcid: 7547031
Giacomeli R, et al. Neuroprotective effects of curcumin lipid-core nanocapsules in a model Alzheimer’s disease induced by beta-amyloid 1–42 peptide in aged female mice. Brain Res. 2019;1721:146325. https://doi.org/10.1016/j.brainres.2019.146325 .
doi: 10.1016/j.brainres.2019.146325
pubmed: 31325424
Mohsen K, et al. Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: in vitro optimization and in vivo pharmacokinetic study. Mater Sci Eng C Mater Biol Appl. 2020;116:111236. https://doi.org/10.1016/j.msec.2020.111236 .
doi: 10.1016/j.msec.2020.111236
pubmed: 32806316
El-Sheridy NA, et al. Itraconazole lipid nanocapsules gel for dermatological applications: in vitro characteristics and treatment of induced cutaneous candidiasis. Colloids Surf B Biointerfaces. 2019;181:623–31. https://doi.org/10.1016/j.colsurfb.2019.05.057 .
doi: 10.1016/j.colsurfb.2019.05.057
pubmed: 31202972
Slusarczyk J, et al. Nanocapsules with polyelectrolyte shell as a platform for 1,25-dihydroxyvitamin D3 neuroprotection: study in organotypic hippocampal slices. Neurotox Res. 2016;30(4):581–92. https://doi.org/10.1007/s12640-016-9652-2 .
doi: 10.1007/s12640-016-9652-2
pubmed: 27422380
pmcid: 5047951
Almouazen E, et al. Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation. Pharm Res. 2013;30(4):1137–46. https://doi.org/10.1007/s11095-012-0949-4 .
doi: 10.1007/s11095-012-0949-4
pubmed: 23225028
Ramalho MJ, et al. PLGA nanoparticles as a platform for vitamin D-based cancer therapy. Beilstein J Nanotechnol. 2015;6:1306–18. https://doi.org/10.3762/bjnano.6.135 .
doi: 10.3762/bjnano.6.135
pubmed: 26199834
pmcid: 4505177
Maradana MR, et al. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. Metabolism. 2018;78:80–94. https://doi.org/10.1016/j.metabol.2017.09.002 .
doi: 10.1016/j.metabol.2017.09.002
pubmed: 28941597
Liu C, et al. Tumor-targeted nanoparticles deliver a vitamin D-based drug payload for the treatment of EGFR tyrosine kinase inhibitor-resistant lung cancer. Mol Pharm. 2018;15(8):3216–26. https://doi.org/10.1021/acs.molpharmaceut.8b00307 .
doi: 10.1021/acs.molpharmaceut.8b00307
pubmed: 29902012
Nicolas S, et al. Polymeric nanocapsules as drug carriers for sustained anticancer activity of calcitriol in breast cancer cells. Int J Pharm. 2018;550(1–2):170–9. https://doi.org/10.1016/j.ijpharm.2018.08.022 .
doi: 10.1016/j.ijpharm.2018.08.022
pubmed: 30118832
Rafique A, et al. Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol. Int J Nanomedicine. 2019;14:2829–46. https://doi.org/10.2147/IJN.S192113 .
doi: 10.2147/IJN.S192113
pubmed: 31114197
pmcid: 6488164
Cai C, et al. Adventitial delivery of nanoparticles encapsulated with 1alpha, 25-dihydroxyvitamin D3 attenuates restenosis in a murine angioplasty model. Sci Rep. 2021;11(1):4772. https://doi.org/10.1038/s41598-021-84444-x .
doi: 10.1038/s41598-021-84444-x
pubmed: 33637886
pmcid: 7910622
Louis JC, et al. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res. 1992;31(1):193–204. https://doi.org/10.1002/jnr.490310125 .
doi: 10.1002/jnr.490310125
pubmed: 1613821
De Vries GH, Boullerne AI. Glial cell lines: an overview. Neurochem Res. 2010;35(12):1978–2000. https://doi.org/10.1007/s11064-010-0318-9 .
doi: 10.1007/s11064-010-0318-9
pubmed: 21127972
pmcid: 7089082
Bernardo A, et al. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol. 2009;68(7):797–808. https://doi.org/10.1097/NEN.0b013e3181aba2c1 .
doi: 10.1097/NEN.0b013e3181aba2c1
pubmed: 19535992
Bernardo A, et al. The nuclear receptor peroxisome proliferator-activated receptor-gamma promotes oligodendrocyte differentiation through mechanisms involving mitochondria and oscillatory Ca2+ waves. Biol Chem. 2013;394(12):1607–14. https://doi.org/10.1515/hsz-2013-0152 .
doi: 10.1515/hsz-2013-0152
pubmed: 23770533
Chu F, et al. The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;318:1–7. https://doi.org/10.1016/j.jneuroim.2018.02.015 .
doi: 10.1016/j.jneuroim.2018.02.015
pubmed: 29606295
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700. https://doi.org/10.1038/nrc2196 .
doi: 10.1038/nrc2196
pubmed: 17721433
Gadhave DG, Kokare CR. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev Ind Pharm. 2019;45(5):839–51. https://doi.org/10.1080/03639045.2019.1576724 .
doi: 10.1080/03639045.2019.1576724
pubmed: 30702966
Gonzalez LF, et al. Intranasal delivery of interferon-beta-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: a promising simple, effective, non-invasive, and low-cost therapy. J Control Release. 2021;331:443–59. https://doi.org/10.1016/j.jconrel.2020.11.019 .
doi: 10.1016/j.jconrel.2020.11.019
pubmed: 33220325
Enkhjargal B, et al. Intranasal administration of vitamin D attenuates blood-brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats. J Cereb Blood Flow Metab. 2017;37(7):2555–66. https://doi.org/10.1177/0271678X16671147 .
doi: 10.1177/0271678X16671147
pubmed: 27671249
Cho SW, et al. Intranasal treatment with 1, 25-dihydroxyvitamin D3 alleviates allergic rhinitis symptoms in a mouse model. Allergy Asthma Immunol Res. 2019;11(2):267–79. https://doi.org/10.4168/aair.2019.11.2.267 .
doi: 10.4168/aair.2019.11.2.267
pubmed: 30661318
pmcid: 6340801
Minne A, et al. The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology. 2007;122(3):316–25. https://doi.org/10.1111/j.1365-2567.2007.02641.x .
doi: 10.1111/j.1365-2567.2007.02641.x
pubmed: 17521369
pmcid: 2266027
Hoekman JD, Hite M, Brunelle A, Relethford J, Ho RJY. Nasal drug delivery device. US9550036 B2; 2017.
Trevino JT, et al. Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials. 2020;10(7).
Asif A, Farooq N. Vitamin D toxicity. In: StatPearls [Internet]. Treasure Island (FL); 2022. PMID: 32491799.
Praet J, et al. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev. 2014;47:485–505. https://doi.org/10.1016/j.neubiorev.2014.10.004 .
doi: 10.1016/j.neubiorev.2014.10.004
pubmed: 25445182
Zhan J, et al. The cuprizone model: dos and do nots. Cells. 2020;9(4). https://doi.org/10.3390/cells9040843 .
Castillo-Rodriguez MLA, et al. Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination. Histochem Cell Biol. 2022;158(1):15–38. https://doi.org/10.1007/s00418-022-02096-y .
doi: 10.1007/s00418-022-02096-y
pubmed: 35380252
pmcid: 9246805
Hashimoto M, et al. The flavonoid Baicalein attenuates cuprizone-induced demyelination via suppression of neuroinflammation. Brain Res Bull. 2017;135:47–52. https://doi.org/10.1016/j.brainresbull.2017.09.007 .
doi: 10.1016/j.brainresbull.2017.09.007
pubmed: 28923306
pmcid: 5700834
Honarvar F, et al. Myelin protection by ursolic acid in cuprizone-induced demyelination in mice. Iran J Pharm Res. 2019;18(4):1978–88. https://doi.org/10.22037/ijpr.2019.112181.13582 .
doi: 10.22037/ijpr.2019.112181.13582
pubmed: 32184863
pmcid: 7059067
Toomey LM, et al. Cuprizone feed formulation influences the extent of demyelinating disease pathology. Sci Rep. 2021;11(1):22594. https://doi.org/10.1038/s41598-021-01963-3 .
doi: 10.1038/s41598-021-01963-3
pubmed: 34799634
pmcid: 8604913
Grishkan IV, et al. 1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization. Proc Natl Acad Sci USA. 2013;110(52):21101–6. https://doi.org/10.1073/pnas.1306072110 .
doi: 10.1073/pnas.1306072110
pubmed: 24324134
pmcid: 3876241
Moore JR, et al. 1,25-Dihydroxyvitamin D(3) increases the methionine cycle, CD4(+) T cell DNA methylation and Helios(+)Foxp3(+) T regulatory cells to reverse autoimmune neurodegenerative disease. J Neuroimmunol. 2018;324:100–14. https://doi.org/10.1016/j.jneuroim.2018.09.008 .
doi: 10.1016/j.jneuroim.2018.09.008
pubmed: 30267995
Ibi M, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001;40(6):761–71. https://doi.org/10.1016/s0028-3908(01)00009-0 .
doi: 10.1016/s0028-3908(01)00009-0
pubmed: 11369030
Chami M, et al. Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination. PLoS ONE. 2017;12(6):e0178622. https://doi.org/10.1371/journal.pone.0178622 .
doi: 10.1371/journal.pone.0178622
pubmed: 28582448
pmcid: 5459450
Aryanpour R, et al. Progesterone therapy induces an M1 to M2 switch in microglia phenotype and suppresses NLRP3 inflammasome in a cuprizone-induced demyelination mouse model. Int Immunopharmacol. 2017;51:131–9. https://doi.org/10.1016/j.intimp.2017.08.007 .
doi: 10.1016/j.intimp.2017.08.007
pubmed: 28830026
Yamamoto S, et al. Ursolic acid treatment suppresses cuprizone-induced demyelination and motor dysfunction via upregulation of IGF-1. J Pharmacol Sci. 2020;144(3):119–22. https://doi.org/10.1016/j.jphs.2020.08.002 .
doi: 10.1016/j.jphs.2020.08.002
pubmed: 32921392
Hausler D, et al. High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium. Brain. 2019;142(9):2737–55. https://doi.org/10.1093/brain/awz190 .
Hausler D, Weber MS. Vitamin D supplementation in central nervous system demyelinating disease-enough is enough. Int J Mol Sci. 2019;20(1). https://doi.org/10.3390/ijms20010218 .
Hausler D, Torke S, Weber MS. High-dose vitamin D-mediated hypercalcemia as a potential risk factor in central nervous system demyelinating disease. Front Immunol. 2020;11:301. https://doi.org/10.3389/fimmu.2020.00301 .
doi: 10.3389/fimmu.2020.00301
pubmed: 32161591
pmcid: 7053380
Fragoso YD, et al. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D. J Neurol Sci. 2014;346(1–2):341–2. https://doi.org/10.1016/j.jns.2014.08.019 .
doi: 10.1016/j.jns.2014.08.019
pubmed: 25183235
Murphy VA, Quentin RS, Stanley IR. Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia. J Neurochem. 1986;47(6):1735–41. https://doi.org/10.1111/j.1471-4159.1986.tb13082.x .
doi: 10.1111/j.1471-4159.1986.tb13082.x
pubmed: 3772375
Tai CY, Quentin RS, Stanley IR. Calcium influxes into brain and cerebrospinal fluid are linearly related to plasma ionized calcium concentration. Brain Res. 1986;385(2):227–36. https://doi.org/10.1016/0006-8993(86)91068-1 .
doi: 10.1016/0006-8993(86)91068-1
pubmed: 3096491
Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87(3):1103–7. https://doi.org/10.1172/JCI115072 .
doi: 10.1172/JCI115072
pubmed: 1705564
pmcid: 329907
Buschmann JP, et al. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J Mol Neurosci. 2012;48(1):66–76. https://doi.org/10.1007/s12031-012-9773-x .
doi: 10.1007/s12031-012-9773-x
pubmed: 22528463
pmcid: 3413816
Clarner T, et al. CXCL10 triggers early microglial activation in the cuprizone model. J Immunol. 2015;194(7):3400–13. https://doi.org/10.4049/jimmunol.1401459 .
doi: 10.4049/jimmunol.1401459
pubmed: 25725102
Ljunggren-Rose A, et al. Anacardic acid induces IL-33 and promotes remyelination in CNS. Proc Natl Acad Sci U S A. 2020;117(35):21527–35. https://doi.org/10.1073/pnas.2006566117 .
doi: 10.1073/pnas.2006566117
pubmed: 32817520
pmcid: 7474623
Gao YH, et al. Treatment with anacardic acid modulates dendritic cell activation and alleviates the disease development of autoimmune neuroinflammation in mice. Biochem Biophys Res Commun. 2022;613:34–40. https://doi.org/10.1016/j.bbrc.2022.04.115 .
doi: 10.1016/j.bbrc.2022.04.115
pubmed: 35526486